Editas Medicine initiated with a Buy at BTIG. BTIG analyst Amanda Murphy initiated Editas Medicine with a Buy rating and $30 price target. Murphy sees Editas having the broadest CRISPR toolbox, noting that “with its IP portfolio, Editas can target ten times as many sites in the genome relative to wild-type spCas9 and roughly 95% of the human genome in total.”
https://thefly.com/landingPageNews.php?id=2861457
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.